We read with great interest the recent article by Wang et al.1 reporting on a psoriatic patient co-affected by HIV-related Kaposi's sarcoma (KS), whose poorly controlled psoriasis was successfully treated with ustekinumab, a fully monoclonal antibody that targets the common p40 subunit shared by interleukins (IL)-12 and IL-23. Interestingly, despite the evidences supporting the role of IL-12 in inhibiting tumorigenesis,2 the authors reported no KS progression after a 16-month follow-up. This article is protected by copyright. All rights reserved.
Comment on: Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma / G. Genovese, A. Tourlaki, E. Berti, L. Brambilla. - In: CLINICAL AND EXPERIMENTAL DERMATOLOGY. - ISSN 0307-6938. - (2019 Jan 28). [10.1111/ced.13935]
Comment on: Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma
G. Genovese
Primo
;A. TourlakiSecondo
;E. BertiPenultimo
;
2019
Abstract
We read with great interest the recent article by Wang et al.1 reporting on a psoriatic patient co-affected by HIV-related Kaposi's sarcoma (KS), whose poorly controlled psoriasis was successfully treated with ustekinumab, a fully monoclonal antibody that targets the common p40 subunit shared by interleukins (IL)-12 and IL-23. Interestingly, despite the evidences supporting the role of IL-12 in inhibiting tumorigenesis,2 the authors reported no KS progression after a 16-month follow-up. This article is protected by copyright. All rights reserved.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Genovese_et_al-2019-Clinical_and_Experimental_Dermatology (1).pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
59.24 kB
Formato
Adobe PDF
|
59.24 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
